Loading...
Insmed Community
NasdaqGS:INSM Community- 1 Narratives written by author
- 1 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
Community Investing Ideas
INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations
Key Takeaways Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration. Strategic investment in market access and R&D aims to sustain long-term profitability and support efficient product launches.Read more
1users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
AN
US$214.12
4.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
92% p.a.
Profit Margin
21.67%
Future PE
100.56x
Price in 2028
US$262.19
